Ipsen (IPN) Eur1
€0.50
(0.46%)
- Add to watchlist
- This stock can be held in a
€0.50
(0.46%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
€0.50
(0.46%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
Contact details
Important dates
General stock information
- Short code:
- IPN
- ISIN:
- FR0010259150
- Market cap:
- €9.10 billion
- Shares in issue:
- 82.70 million
- Sector:
- Pharmaceuticals
- Exchange:
- Euronext Paris
- Country:
- France
- Currency:
- Euro
- Indices:
- Euronext 100
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.